REAGILA, known generically as cariprazine, is an atypical antipsychotic medication primarily used in the treatment of schizophrenia and bipolar disorder. It functions by balancing certain neurotransmitters in the brain, such as dopamine and serotonin, which can significantly improve symptoms like hallucinations, delusions, mood swings, and depression. REAGILA is distinguished by its dual action as both a partial agonist and antagonist at dopamine D2 and serotonin 5-HT1A receptors, offering a unique approach to managing the complex symptoms associated with these mental health conditions. It is available in capsule form and is usually taken once daily, with or without food, as prescribed by a healthcare professional. Like all medications, REAGILA may have side effects, and its use should be closely monitored by a healthcare provider to ensure its efficacy and safety for the individual patient.